Report cover image

Viral Vector and Plasmid DNA Manufacturing Market, By Vector Type (Viral Vectors, Non-viral Vectors); By Workflow (Upstream Processing, Downstream Processing); By Disease Indication (Cancer, Genetic Disorders, Infectious Diseases, Cardiovascular Disorders

Publisher BlueWeave Consulting
Published Jul 08, 2025
Length 527 Pages
SKU # BLWC20227917

Description

Global Viral Vector and Plasmid DNA Manufacturing Market Zooming 3.4X to Cross USD 21 Billion by 2031
Global Viral Vector and Plasmid DNA Manufacturing Market is flourishing because of the escalating demand for gene and cell therapies, an increasing number of regulatory approvals for viral vector-based drugs and vaccines, and the sustained growth in clinical trial activities.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated Global Viral Vector and Plasmid DNA Manufacturing Market size at USD 6.26 billion in 2024. During the forecast period between 2025 and 2031, BlueWeave expects Global Viral Vector and Plasmid DNA Manufacturing Market size to expand at a robust CAGR of 19.2% reaching a value of USD 21.39 billion by 2031. The growth of Viral Vector and Plasmid DNA Manufacturing Market across the regions is propelled by significant advancements in gene therapy, which fundamentally rely on high-quality viral vectors and plasmid DNA. This growth is further propelled by innovations in manufacturing techniques—such as transient transfection, suspension cell culture systems, and the adoption of single-use bioreactors like Pall's iCELLis—that enhance efficiency, scalability, and cost-effectiveness. Increased investments in cell and gene therapy research, evidenced by funding initiatives such as Canada's USD 1.89 million grant to iVexSol, are intensifying demand, while market consolidation through strategic acquisitions, like Merck KGaA's purchase of Exelead, strengthens CDMO service portfolios. Moreover, stringent regulatory compliance is crucial for market access and quality assurance, and critically, viral vectors and plasmid DNA remain indispensable to gene therapy with no currently effective alternatives.

Impact of Escalating Geopolitical Tensions on Global Viral Vector and Plasmid DNA Manufacturing Market

Intensifying geopolitical tensions could disrupt the growth of Global Viral Vector and Plasmid DNA Manufacturing Market. Disruptions in international trade, limitations on cross-border collaborations, and the imposition of sanctions on specific countries can severely impede the global supply chain for crucial raw materials and equipment. These tensions risk delaying the transport of essential components, increasing operational costs, and creating regulatory uncertainties. Furthermore, reduced foreign investment and restricted access to global talent pools could stifle innovation and hinder manufacturing expansion. Given the market's reliance on international partnerships and specialized supply chains, sustained geopolitical instability represents a serious challenge to its continued growth and the timely delivery of vital gene therapies.

Asia Pacific Dominates Global Viral Vector and Plasmid DNA Manufacturing Market

Asia Pacific is expected to maintain its leading position in the Global Viral Vector and Plasmid DNA Manufacturing Market throughout the forecast period. The dominance is driven by favorable regulatory advancements, increasing gene therapy demand, and strong government support. China leads this expansion due to its progressive regulatory framework for cell-based research and rapid vaccine commercialization, as seen with the Advaccine-INOVIO COVID-19 DNA vaccine agreement. Significant regional investments by VectorBuilder, WuXi Biologics, and Bharat Biotech (India's USD 75M CGT facility) highlight growing capabilities. Government incentives, streamlined approvals, and expanding biopharma infrastructure are collectively boosting production, affordability, and Asia Pacific's crucial global market position.

Competitive Landscape
Major companies in Global Viral Vector and Plasmid DNA Manufacturing Market include Catalent Inc., Thermo Fisher Scientific, Lonza Group, Oxford Biomedica, Fujifilm Diosynth Biotechnologies, Cobra Biologics, Wuxi Biologics, Takara Bio Inc., Waisman Biomanufacturing, Genezen Laboratories, Batavia Biosciences, Miltenyi Biotec GmbH, SIRION Biotech GmbH, Virovek Incorporation, BioNTech IMFS GmbH, Audentes Therapeutics, BioMarin Pharmaceutical, and RegenxBio, Inc. The presence of high number of companies intensify the market competition as they compete to gain a significant market share. These companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches to further enhance their market share.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and Global Viral Vector and Plasmid DNA Manufacturing Market statistics. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in Global Viral Vector and Plasmid DNA Manufacturing Market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

Table of Contents

527 Pages
1. Research Framework
1.1. Research Objective
1.2. Viral Vector and Plasmid DNA Manufacturing Market Overview
1.3. Market Segmentation
2. Executive Summary
3. Global Viral Vector and Plasmid DNA Manufacturing Market Insights
3.1. End User Value Chain Analysis
3.2. DROC Analysis
3.2.1. Growth Drivers
3.2.1.1. Rising Demand for Gene & Cell Therapies
3.2.1.2. Increasing Approvals for Viral Vector-based Drugs & Vaccines
3.2.1.3. Growing Number of Clinical Trials
3.2.2. Restraints
3.2.2.1. High Manufacturing Costs
3.2.2.2. Stringent Regulatory Requirements
3.2.3. Opportunities
3.2.3.1. Expansion of CDMO Partnerships
3.2.3.2. Emerging Market in Asia Pacific
3.2.4. Challenges
3.2.4.1. Capacity Constraints
3.2.4.2. Supply Chain Disruptions
3.3. Technological Advancements/Recent Developments
3.4. Regulatory Framework
3.5. Porter’s Five Forces Analysis
3.5.1. Bargaining Power of Suppliers
3.5.2. Bargaining Power of Buyers
3.5.3. Threat of New Entrants
3.5.4. Threat of Substitutes
3.5.5. Intensity of Rivalry
4. Global Viral Vector and Plasmid DNA Manufacturing Market: Marketing Strategies
5. Global Viral Vector and Plasmid DNA Manufacturing Market: Pricing Analysis
6. Global Viral Vector and Plasmid DNA Manufacturing Market: Geography Analysis
6.1. Global Viral Vector and Plasmid DNA Manufacturing Market, Geographical Analysis, 2024
6.2. Global Viral Vector and Plasmid DNA Manufacturing, Market Attractiveness Analysis, 2024–2031
7. Global Viral Vector and Plasmid DNA Manufacturing Market Overview
7.1. Market Size & Forecast, 2019–2031
7.1.1. By Value (USD Billion)
7.2. Market Share & Forecast
7.2.1. By Vector Type
7.2.1.1. Viral Vectors
7.2.1.2. Non-viral Vectors
7.2.2. By Workflow
7.2.2.1. Upstream Processing
7.2.2.2. Downstream Processing
7.2.3. By Disease Indication
7.2.3.1. Cancer
7.2.3.2. Genetic Disorders
7.2.3.3. Infectious Diseases
7.2.3.4. Cardiovascular Disorders
7.2.3.5. Neurological Disorders
7.2.3.6. Others
7.2.4. By End User
7.2.4.1. Pharmaceutical & Biopharmaceutical Companies
7.2.4.2. Contract Development & Manufacturing Organizations
7.2.4.3. Research Institutes
7.2.4.4. Academic & Government Research Centers
7.2.5. By Region
7.2.5.1. North America
7.2.5.2. Europe
7.2.5.3. The Asia Pacific
7.2.5.4. Latin America
7.2.5.5. Middle East and Africa
8. North America Viral Vector and Plasmid DNA Manufacturing Market
8.1. Market Size & Forecast, 2019–2031
8.1.1. By Value (USD Billion)
8.2. Market Share & Forecast
8.2.1. By Vector Type
8.2.2. By Workflow
8.2.3. By Disease Indication
8.2.4. By End User
8.2.5. By Country
8.2.5.1. United States
8.2.5.1.1. By Vector Type
8.2.5.1.2. By Workflow
8.2.5.1.3. By Disease Indication
8.2.5.1.4. By End User
8.2.5.2. Canada
8.2.5.2.1. By Vector Type
8.2.5.2.2. By Workflow
8.2.5.2.3. By Disease Indication
8.2.5.2.4. By End User
9. Europe Viral Vector and Plasmid DNA Manufacturing Market
9.1. Market Size & Forecast, 2019–2031
9.1.1. By Value (USD Billion)
9.2. Market Share & Forecast
9.2.1. By Vector Type
9.2.2. By Workflow
9.2.3. By Disease Indication
9.2.4. By End User
9.2.5. By Country
9.2.5.1. Germany
9.2.5.1.1. By Vector Type
9.2.5.1.2. By Workflow
9.2.5.1.3. By Disease Indication
9.2.5.1.4. By End User
9.2.5.2. United Kingdom
9.2.5.2.1. By Vector Type
9.2.5.2.2. By Workflow
9.2.5.2.3. By Disease Indication
9.2.5.2.4. By End User
9.2.5.3. Italy
9.2.5.3.1. By Vector Type
9.2.5.3.2. By Workflow
9.2.5.3.3. By Disease Indication
9.2.5.3.4. By End User
9.2.5.4. France
9.2.5.4.1. By Vector Type
9.2.5.4.2. By Workflow
9.2.5.4.3. By Disease Indication
9.2.5.4.4. By End User
9.2.5.5. Spain
9.2.5.5.1. By Vector Type
9.2.5.5.2. By Workflow
9.2.5.5.3. By Disease Indication
9.2.5.5.4. By End User
9.2.5.6. Belgium
9.2.5.6.1. By Vector Type
9.2.5.6.2. By Workflow
9.2.5.6.3. By Disease Indication
9.2.5.6.4. By End User
9.2.5.7. Russia
9.2.5.7.1. By Vector Type
9.2.5.7.2. By Workflow
9.2.5.7.3. By Disease Indication
9.2.5.7.4. By End User
9.2.5.8. The Netherlands
9.2.5.8.1. By Vector Type
9.2.5.8.2. By Workflow
9.2.5.8.3. By Disease Indication
9.2.5.8.4. By End User
9.2.5.9. Rest of Europe
9.2.5.9.1. By Vector Type
9.2.5.9.2. By Workflow
9.2.5.9.3. By Disease Indication
9.2.5.9.4. By End User
10. Asia Pacific Viral Vector and Plasmid DNA Manufacturing Market
10.1. Market Size & Forecast, 2019–2031
10.1.1. By Value (USD Billion)
10.2. Market Share & Forecast
10.2.1. By Vector Type
10.2.2. By Workflow
10.2.3. By Disease Indication
10.2.4. By End User
10.2.5. By Country
10.2.5.1. China
10.2.5.1.1. By Vector Type
10.2.5.1.2. By Workflow
10.2.5.1.3. By Disease Indication
10.2.5.1.4. By End User
10.2.5.2. India
10.2.5.2.1. By Vector Type
10.2.5.2.2. By Workflow
10.2.5.2.3. By Disease Indication
10.2.5.2.4. By End User
10.2.5.3. Japan
10.2.5.3.1. By Vector Type
10.2.5.3.2. By Workflow
10.2.5.3.3. By Disease Indication
10.2.5.3.4. By End User
10.2.5.4. South Korea
10.2.5.4.1. By Vector Type
10.2.5.4.2. By Workflow
10.2.5.4.3. By Disease Indication
10.2.5.4.4. By End User
10.2.5.5. Australia & New Zealand
10.2.5.5.1. By Vector Type
10.2.5.5.2. By Workflow
10.2.5.5.3. By Disease Indication
10.2.5.5.4. By End User
10.2.5.6. Indonesia
10.2.5.6.1. By Vector Type
10.2.5.6.2. By Workflow
10.2.5.6.3. By Disease Indication
10.2.5.6.4. By End User
10.2.5.7. Malaysia
10.2.5.7.1. By Vector Type
10.2.5.7.2. By Workflow
10.2.5.7.3. By Disease Indication
10.2.5.7.4. By End User
10.2.5.8. Singapore
10.2.5.8.1. By Vector Type
10.2.5.8.2. By Workflow
10.2.5.8.3. By Disease Indication
10.2.5.8.4. By End User
10.2.5.9. Vietnam
10.2.5.9.1. By Vector Type
10.2.5.9.2. By Workflow
10.2.5.9.3. By Disease Indication
10.2.5.9.4. By End User
10.2.5.10. Rest of APAC
10.2.5.10.1. By Vector Type
10.2.5.10.2. By Workflow
10.2.5.10.3. By Disease Indication
10.2.5.10.4. By End User
11. Latin America Viral Vector and Plasmid DNA Manufacturing Market
11.1. Market Size & Forecast, 2019–2031
11.1.1. By Value (USD Billion)
11.2. Market Share & Forecast
11.2.1. By Vector Type
11.2.2. By Workflow
11.2.3. By Disease Indication
11.2.4. By End User
11.2.5. By Country
11.2.5.1. Brazil
11.2.5.1.1. By Vector Type
11.2.5.1.2. By Workflow
11.2.5.1.3. By Disease Indication
11.2.5.1.4. By End User
11.2.5.2. Mexico
11.2.5.2.1. By Vector Type
11.2.5.2.2. By Workflow
11.2.5.2.3. By Disease Indication
11.2.5.2.4. By End User
11.2.5.3. Argentina
11.2.5.3.1. By Vector Type
11.2.5.3.2. By Workflow
11.2.5.3.3. By Disease Indication
11.2.5.3.4. By End User
11.2.5.4. Peru
11.2.5.4.1. By Vector Type
11.2.5.4.2. By Workflow
11.2.5.4.3. By Disease Indication
11.2.5.4.4. By End User
11.2.5.5. Rest of LATAM
11.2.5.5.1. By Vector Type
11.2.5.5.2. By Workflow
11.2.5.5.3. By Disease Indication
11.2.5.5.4. By End User
12. Middle East & Africa Viral Vector and Plasmid DNA Manufacturing Market
12.1. Market Size & Forecast, 2019–2031
12.1.1. By Value (USD Billion)
12.2. Market Share & Forecast
12.2.1. By Vector Type
12.2.2. By Workflow
12.2.3. By Disease Indication
12.2.4. By End User
12.2.5. By Country
12.2.5.1. Saudi Arabia
12.2.5.1.1. By Vector Type
12.2.5.1.2. By Workflow
12.2.5.1.3. By Disease Indication
12.2.5.1.4. By End User
12.2.5.2. UAE
12.2.5.2.1. By Vector Type
12.2.5.2.2. By Workflow
12.2.5.2.3. By Disease Indication
12.2.5.2.4. By End User
12.2.5.3. Qatar
12.2.5.3.1. By Vector Type
12.2.5.3.2. By Workflow
12.2.5.3.3. By Disease Indication
12.2.5.3.4. By End User
12.2.5.4. Kuwait
12.2.5.4.1. By Vector Type
12.2.5.4.2. By Workflow
12.2.5.4.3. By Disease Indication
12.2.5.4.4. By End User
12.2.5.5. South Africa
12.2.5.5.1. By Vector Type
12.2.5.5.2. By Workflow
12.2.5.5.3. By Disease Indication
12.2.5.5.4. By End User
12.2.5.6. Nigeria
12.2.5.6.1. By Vector Type
12.2.5.6.2. By Workflow
12.2.5.6.3. By Disease Indication
12.2.5.6.4. By End User
12.2.5.7. Algeria
12.2.5.7.1. By Vector Type
12.2.5.7.2. By Workflow
12.2.5.7.3. By Disease Indication
12.2.5.7.4. By End User
12.2.5.8. Rest of MEA
12.2.5.8.1. By Vector Type
12.2.5.8.2. By Workflow
12.2.5.8.3. By Disease Indication
12.2.5.8.4. By End User
13. Competitive Landscape
13.1. List of Key Players and Their Types
13.2. Global Viral Vector and Plasmid DNA Manufacturing Company Market Share Analysis, 2024
13.3. Competitive Benchmarking, By Operating Parameters
13.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships)
14. Impact of Escalating Geopolitical Tensions on Global Viral Vector and Plasmid DNA Manufacturing Market
15. Company Profiles (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, SWOT Analysis)
15.1. Catalent Inc.
15.2. Thermo Fisher Scientific
15.3. Lonza Group
15.4. Oxford Biomedica
15.5. Fujifilm Diosynth Biotechnologies
15.6. Cobra Biologics
15.7. Wuxi Biologics
15.8. Takara Bio Inc.
15.9. Waisman Biomanufacturing
15.10. Genezen Laboratories
15.11. Batavia Biosciences
15.12. Miltenyi Biotec GmbH
15.13. SIRION Biotech GmbH
15.14. Virovek Incorporation
15.15. BioNTech IMFS GmbH
15.16. Audentes Therapeutics
15.17. BioMarin Pharmaceutical
15.18. RegenxBio, Inc.
15.19. Other Prominent Players
16. Key Strategic Recommendations
17. Research Methodology
17.1. Qualitative Research
17.1.1. Primary & Secondary Research
17.2. Quantitative Research
17.3. Market Breakdown & Data Triangulation
17.3.1. Secondary Research
17.3.2. Primary Research
17.4. Breakdown of Primary Research Respondents, By Region
17.5. Assumptions & Limitations
*Financial information of non-listed companies can be provided as per availability.
**The segmentation and the companies are subject to modifications based on in-depth secondary research for the final deliverable

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us